Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 80

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Asthma+1

Not recruiting

Bioequivalence study of fluticasone propionate and salmeterol xinafoate inhalation powder in healthy volunteers for asthma treatment

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · Healthy volunteers
  • Substances:Salmeterol Xinafoate
  • Sponsor:Respirent Pharmaceuticals Co. Ltd.

Inflammation

Not recruiting

A study to evaluate how JNJ-77242113 is absorbed by the body in healthy participants for the treatment of inflammatory diseases.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

A study of the effects of AGMB-129 and midazolam in healthy participants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Midazolam
  • Sponsor:Agomab Spain S.L.U.

Asthma+1

Not recruiting

Bioequivalence of fluticasone propionate and salmeterol xinafoate inhalation powder for asthma in healthy volunteers

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · Healthy volunteers
  • Substances:Salmeterol Xinafoate
  • Sponsor:Respirent Pharmaceuticals Co. Ltd.

Dermatitis atopic

Not recruiting

Safety and Tolerability of Topical Iodine (DLQ03) in Patients with Mild to Moderate Atopic Dermatitis Colonized with Staphylococcus aureus

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Dermaliq Therapeutics Inc.

Asthma

Not recruiting

Comparison of montelukast 10 mg capsules and montelukast 10 mg film-coated tablets in healthy volunteers to evaluate how the medicine is absorbed.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Montelukast
  • Sponsor:Laboratorios Alter S.A.

Eosinophilic oesophagitis+3

Not recruiting

Pharmacokinetics and Safety of Single Oral Etrasimod Arginine in Healthy Adults for Ulcerative Colitis Using At-Home Tasso Sampling and Wearable Monitoring

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Seasonal allergy

Not recruiting

Effect of a single oral dose of acalabrutinib on skin prick test wheal size in adults with grass pollen allergy using histamine dihydrochloride and phleum pratense

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Alk-Abello A/S

Asthma

Not recruiting

Evaluation of lung delivery and systemic exposure of inhaled beclometasone dipropionate and beclometasone dipropionate anhydrous for asthma in healthy adult volunteers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Multiple sclerosis+1

Not recruiting

Phase 1 study of remibrutinib exposure in cerebrospinal fluid after oral dosing in healthy participants

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Autoimmune disorder

Not recruiting

Safety and Pharmacokinetics of Oral PTC844 in Healthy Participants for Autoimmune Disorder Treatment

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:PTC Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.